EGFR and cancer: Furthermore, DOX-loaded EGFR-MIP NPs decreased the cell viability of EGFR-overexpressing MDA-MB-468 cancer cells (lower than 75%) in comparison to free DOX (more than 90%) and control NPs (~100%).